Wild-type (senile) amyloidosis other diagnostic studies: Difference between revisions
Aditya Ganti (talk | contribs) |
No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Wild-type (senile) amyloidosis}} | {{Wild-type (senile) amyloidosis}} | ||
{{CMG}} | {{CMG}}{{AE}}{{ADG}} | ||
==Overview== | ==Overview== |
Revision as of 18:58, 19 December 2019
Wild-type (senile) amyloidosis Microchapters |
Differentiating Wild-type (senile) amyloidosis from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Wild-type (senile) amyloidosis other diagnostic studies On the Web |
American Roentgen Ray Society Images of Wild-type (senile) amyloidosis other diagnostic studies |
FDA on Wild-type (senile) amyloidosis other diagnostic studies |
CDC on Wild-type (senile) amyloidosis other diagnostic studies |
Wild-type (senile) amyloidosis other diagnostic studies in the news |
Blogs on Wild-type (senile) amyloidosis other diagnostic studies |
Risk calculators and risk factors for Wild-type (senile) amyloidosis other diagnostic studies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]
Overview
Other Diagnostic Studies
Other diagnostic studies that help in diagnosing wild type amyloidosis include cardiac biomarkers, histopathological diagnosis and genetic testing.[1]
Other Diagnostic Studies | |
---|---|
Cardiac biomarkers |
|
Histopathological diagnosis |
|
Genetic testing |
|
References
- ↑ Damy T, Deux JF, Moutereau S, Guendouz S, Mohty D, Rappeneau S, Guellich A, Hittinger L, Loric S, Lefaucheur JP, Plante-Bordeneuve V (December 2013). "Role of natriuretic peptide to predict cardiac abnormalities in patients with hereditary transthyretin amyloidosis". Amyloid. 20 (4): 212–20. doi:10.3109/13506129.2013.825240. PMID 23964755.